Viagra could hold key to halting Peyronie’s disease

A new study published in The Journal of Sexual Medicine suggests that combining two widely prescribed drug classes may provide the first effective treatment for early-stage Peyronie’s disease.

Peyronie’s disease is a condition characterized by the development of fibrous scar tissue inside the penis, which leads to a curvature of the organ during erection.

The research indicates that a combination therapy approach significantly improves outcomes for patients in the early stages of the condition. According to the study, 43% of patients who received the combination of the two drug classes experienced an improvement in penile curvature.

This success rate was almost three times higher than the improvement observed in the comparison group.

Combination Therapy Approach

The treatment strategy involves the simultaneous use of two different categories of medication. One of these drug classes includes medications such as Viagra, which is commonly prescribed to treat erectile dysfunction.

While medications like Viagra are traditionally used to increase blood flow and relax muscles in the blood vessel walls to treat impotence, the study explored their efficacy when paired with another drug class specifically to halt or reverse the curvature associated with Peyronie’s disease.

The findings suggest that this dual-action approach may be more effective at treating the underlying issues of early-stage Peyronie’s disease than using a single medication alone.

Clinical Significance

The ability to improve penile curvature in the early stages of the disease is a significant development, as the condition often progresses to a more permanent state of scarring if not treated effectively during the initial phase.

By utilizing widely prescribed drug classes, the proposed treatment may offer a more accessible path for patients seeking to manage the physical changes caused by the disease.

The results published on May 14, 2026, highlight the potential for combination therapies to address the mechanical and vascular challenges presented by the fibrous plaque typical of Peyronie’s disease.